- Home
- AKA vs TNYA Comparison
AKA vs TNYA Comparison
Compare AKA & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- TNYA
- Stock Information
- Founded
- AKA 2018
- TNYA 2016
- Country
- AKA United States
- TNYA United States
- Employees
- AKA N/A
- TNYA N/A
- Industry
- AKA Catalog/Specialty Distribution
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- AKA Consumer Discretionary
- TNYA Health Care
- Exchange
- AKA Nasdaq
- TNYA Nasdaq
- Market Cap
- AKA 110.4M
- TNYA 111.1M
- IPO Year
- AKA 2021
- TNYA 2021
- Fundamental
- Price
- AKA $11.01
- TNYA $0.83
- Analyst Decision
- AKA Buy
- TNYA Strong Buy
- Analyst Count
- AKA 4
- TNYA 5
- Target Price
- AKA $22.50
- TNYA $8.60
- AVG Volume (30 Days)
- AKA 5.4K
- TNYA 2.5M
- Earning Date
- AKA 08-06-2025
- TNYA 08-07-2025
- Dividend Yield
- AKA N/A
- TNYA N/A
- EPS Growth
- AKA N/A
- TNYA N/A
- EPS
- AKA N/A
- TNYA N/A
- Revenue
- AKA $586,514,000.00
- TNYA N/A
- Revenue This Year
- AKA $6.60
- TNYA N/A
- Revenue Next Year
- AKA $4.14
- TNYA N/A
- P/E Ratio
- AKA N/A
- TNYA N/A
- Revenue Growth
- AKA 8.09
- TNYA N/A
- 52 Week Low
- AKA $7.00
- TNYA $0.36
- 52 Week High
- AKA $32.25
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- AKA 46.25
- TNYA 65.61
- Support Level
- AKA $10.75
- TNYA $0.79
- Resistance Level
- AKA $11.54
- TNYA $0.90
- Average True Range (ATR)
- AKA 0.40
- TNYA 0.07
- MACD
- AKA 0.04
- TNYA 0.01
- Stochastic Oscillator
- AKA 22.47
- TNYA 68.09
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.